AbbVie receives FDA approval for ultra-rare blood cancer ADC acquired from ImmunoGen

AbbVie announced that the U.S. Food and Drug Administration has granted approval for an antibody-drug conjugate targeting an ultra-rare, aggressive form of blood cancer.

The therapy was obtained through AbbVie's $10.1 billion acquisition of ImmunoGen, expanding its oncology pipeline with a novel ADC platform.

The approval provides a new treatment option for patients with this rare disease and underscores AbbVie's strategy of growth through strategic acquisitions.